Terms: = Kidney tumors AND Nuclear matrix protein 22
17 results:
1. Early detection of kidney cancer using urinary proteins: a truly non-invasive strategy.
Flitcroft JG; Verheyen J; Vemulkar T; Welbourne EN; Rossi SH; Welsh SJ; Cowburn RP; Stewart GD
BJU Int; 2022 Mar; 129(3):290-303. PubMed ID: 34570419
[TBL] [Abstract] [Full Text] [Related]
2. Use of the nuclear matrix protein 22 BladderChek Test for the Detection of Primary and Recurrent Urothelial Carcinoma.
Xia CS; Fan CH; Su M; Wang QS; Bao HZ
Dis Markers; 2020; 2020():3424039. PubMed ID: 32454904
[TBL] [Abstract] [Full Text] [Related]
3. [Transurethral flexible ureteroscopic holmium laser resection for tumors of renal pelvis: 6 cases report and literature review].
Hao YC; Chen K; Liu YQ; Lu J; Xiao CL; Ma LL
Beijing Da Xue Xue Bao Yi Xue Ban; 2018 Oct; 50(5):816-821. PubMed ID: 30337741
[TBL] [Abstract] [Full Text] [Related]
4. Urine gamma-synuclein as a biomarker for the diagnosis of bladder cancer.
Liu C; Shi B; Hao C; Wang Q; Lv Q; Xing N; Shou J; Qu L; Gao Y; Qin C; Zhao J; Shou C
Oncotarget; 2016 Jul; 7(28):43432-43441. PubMed ID: 27223068
[TBL] [Abstract] [Full Text] [Related]
5. Long-term outcomes in a high-risk bladder cancer screening cohort.
Starke N; Singla N; Haddad A; Lotan Y
BJU Int; 2016 Apr; 117(4):611-7. PubMed ID: 25891519
[TBL] [Abstract] [Full Text] [Related]
6. Outcomes of a bladder cancer screening program using home hematuria testing and molecular markers.
Bangma CH; Loeb S; Busstra M; Zhu X; El Bouazzaoui S; Refos J; Van Der Keur KA; Tjin S; Franken CG; van Leenders GJ; Zwarthoff EC; Roobol MJ
Eur Urol; 2013 Jul; 64(1):41-7. PubMed ID: 23478169
[TBL] [Abstract] [Full Text] [Related]
7. The clinical usefulness of nuclear matrix protein-22 in patients with end-stage renal disease and microscopic hematuria.
Trojan B; Tang A; Chandrapal J; Filleur S; Nelius T
Ren Fail; 2013; 35(1):72-6. PubMed ID: 23151051
[TBL] [Abstract] [Full Text] [Related]
8. Influence of renal excretory function on the performance of urine based markers to detect bladder cancer.
Todenhöfer T; Hennenlotter J; Witstruk M; Gakis G; Aufderklamm S; Kuehs U; Stenzl A; Schwentner C
J Urol; 2012 Jan; 187(1):68-73. PubMed ID: 22088333
[TBL] [Abstract] [Full Text] [Related]
9. [Expression and clinical significance of nuclear matrix protein 22 and cytokeratin 18 in transitional cell carcinoma of the bladder].
Song JW; DU LL; Zhao XW; Jing JX; Han CZ; Cui Y; Liu JW; Hao HL; Wang ZG; Mi ZG
Zhonghua Zhong Liu Za Zhi; 2009 Apr; 31(4):274-7. PubMed ID: 19615282
[TBL] [Abstract] [Full Text] [Related]
10. Urinary nuclear matrix protein 22 for diagnosis of renal cell carcinoma.
Kaya K; Ayan S; Gokce G; Kilicarslan H; Yildiz E; Gultekin EY
Scand J Urol Nephrol; 2005; 39(1):25-9. PubMed ID: 15764267
[TBL] [Abstract] [Full Text] [Related]
11. [The clinical efficacy of Bladder Chek NMP22 in urothelial cancer].
Yokoyama T; Sekigawa R; Hayashi T; Horita S; Kanamuro T; Nonami Y; Sawada T; Nishikawa T; Kobayashi M; Yamaguchi Y; Ishida H; Goya N; Nakazawa H; Toma H
Rinsho Byori; 2004 Mar; 52(3):199-203. PubMed ID: 15137316
[TBL] [Abstract] [Full Text] [Related]
12. Clinical study of urine NMP 22 (nuclear matrix protein 22) as a tumor marker in urinary epithelial cancer.
Takeuchi Y; Sawada Y; Yabuki D; Masuda E; Satou D; Kuroda K; Tajima M; Sawamura Y; Matsushima M
Aktuelle Urol; 2003 Jul; 34(4):265-6. PubMed ID: 14566681
[TBL] [Abstract] [Full Text] [Related]
13. Value of urinary NMP-22 in patients with renal cell carcinoma.
Ozer G; Altinel M; Kocak B; Yazicioglu A; Gonenc F
Urology; 2002 Oct; 60(4):593-7. PubMed ID: 12385914
[TBL] [Abstract] [Full Text] [Related]
14. [Availability of NMP22 (nuclear matrix protein 22) for the diagnosis of urothelial cancer].
Akagashi K; Tanda H; Kato S; Ohnishi S; Nakajima H; Nanbu A; Nitta T; Koroku M
Hinyokika Kiyo; 2001 May; 47(5):307-10. PubMed ID: 11433749
[TBL] [Abstract] [Full Text] [Related]
15. Urinary NMP22 and renal cell carcinoma.
Huang S; Rhee E; Patel H; Park E; Kaswick J
Urology; 2000 Feb; 55(2):227-30. PubMed ID: 10688084
[TBL] [Abstract] [Full Text] [Related]
16. [Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer--screening for urothelial cancer in patients with microscopic hematuria. NMP Study Group].
Akaza H; Miyanaga N; Tsukamoto T; Ishikawa S; Noguchi R; Ohtani M; Kawabe K; Kubota Y; Fujita K; Obata K; Hirao Y; Kotake T; Ohmori H; Kumazawa J; Koiso K
Gan To Kagaku Ryoho; 1997 May; 24(7):837-42. PubMed ID: 9170522
[TBL] [Abstract] [Full Text] [Related]
17. [Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer--NMP22 as a urinary marker for surveillance of bladder cancer. NMP22 Study Group].
Akaza H; Miyanaga N; Tsukamoto T; Ishikawa S; Noguchi R; Ohtani M; Kawabe K; Kubota Y; Fujita K; Obata K; Hirao Y; Kotake T; Ohmori H; Kumazawa J; Koiso K
Gan To Kagaku Ryoho; 1997 May; 24(7):829-36. PubMed ID: 9170521
[TBL] [Abstract] [Full Text] [Related]
